Compare NFE & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NFE | NGNE |
|---|---|---|
| Founded | 2014 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil/Gas Transmission | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 324.4M | 327.8M |
| IPO Year | 2018 | 2014 |
| Metric | NFE | NGNE |
|---|---|---|
| Price | $0.64 | $27.21 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | $7.63 | ★ $63.57 |
| AVG Volume (30 Days) | ★ 7.9M | 148.2K |
| Earning Date | 04-13-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 0.93 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,504,037,000.00 | N/A |
| Revenue This Year | $110.34 | N/A |
| Revenue Next Year | $3.54 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.56 | $11.78 |
| 52 Week High | $6.37 | $37.27 |
| Indicator | NFE | NGNE |
|---|---|---|
| Relative Strength Index (RSI) | 39.91 | 65.32 |
| Support Level | $0.56 | $19.40 |
| Resistance Level | $0.77 | $29.05 |
| Average True Range (ATR) | 0.07 | 1.88 |
| MACD | 0.02 | 0.45 |
| Stochastic Oscillator | 21.80 | 81.15 |
New Fortress Energy Inc is an integrated gas-to-power company. Its business model spans the entire production and delivery chain from natural gas procurement and liquefaction to logistics, shipping, terminals, and conversion or development of a natural gas-fired generation. It has invested in floating, liquefied natural gas vessels to lower the cost of acquiring gas while securing a long-term supply for its terminals. Its segments include Terminals & Infrastructure, and Ships. It generates the majority of its revenue from the Terminals & Infrastructure segment.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.